middle.news
Rhythm Biosciences Secures Up to $6M Underwriting to Boost Cancer Test Rollout
9:10am on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
Rhythm Biosciences Secures Up to $6M Underwriting to Boost Cancer Test Rollout
9:10am on Wednesday 25th of February, 2026 AEDT
Key Points
Underwriting agreement with CPS Capital Group for listed options expiring March 31, 2026
Minimum $4.5 million and maximum $6 million funding secured before costs
Up to 30 million shortfall shares to be issued if options remain unexercised
Funds targeted for commercialisation of ColoSTAT® and geneType™ platforms and working capital
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RHYTHM BIOSCIENCES (ASX:RHY)
OPEN ARTICLE